Compare FXNC & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | ACRS |
|---|---|---|
| Founded | 1907 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.6M | 230.8M |
| IPO Year | N/A | 2015 |
| Metric | FXNC | ACRS |
|---|---|---|
| Price | $24.51 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 15.7K | ★ 1.4M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 10.94 | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | ★ $81,206,000.00 | $15,742,000.00 |
| Revenue This Year | $57.18 | N/A |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $19.70 | ★ N/A |
| Revenue Growth | ★ 66.40 | N/A |
| 52 Week Low | $18.26 | $1.05 |
| 52 Week High | $26.97 | $4.24 |
| Indicator | FXNC | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 64.58 |
| Support Level | $23.07 | $2.34 |
| Resistance Level | $24.45 | $2.57 |
| Average True Range (ATR) | 0.67 | 0.21 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 83.80 | 87.31 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.